Guideline Summary: Management of Sexual Dysfunction in Postmenopausal Women

Stepwise Treatment Algorithm

Begin treatment with vaginal lubricants for sexual activity and moisturizers applied 3–5 times per week to the vagina, vaginal opening, and external vulvar folds before any hormonal therapy is considered. 1, 3
If conservative measures fail or symptoms are severe at presentation, initiate low‑dose vaginal estrogen as the next step. 1, 3
Vaginal estrogen is the most effective therapy for vaginal dryness‑related sexual dysfunction, alleviating itching, discomfort, and painful intercourse. 4, 2, 5

A cohort of ~50,000 breast‑cancer patients followed up to 20 years showed no increase in breast‑cancer‑specific mortality with vaginal estrogen use. 4, 2, 5

In hormone‑positive breast‑cancer survivors who remain symptomatic after conservative measures, low‑dose vaginal estrogen may be offered after a thorough risk‑benefit discussion. 1, 3
In postmenopausal breast‑cancer survivors on aromatase inhibitors, an estradiol‑releasing vaginal ring was safe and improved vaginal atrophy and sexual function in a study of 76 women. 4, 2
For women on aromatase inhibitors who have not responded to prior therapy, vaginal DHEA can be considered, but it should be used cautiously because it may raise circulating androgens and potentially affect AI activity. 1, 3 [4, 2]

Ospemifene may be prescribed to postmenopausal women without current or prior breast cancer who experience dyspareunia or vaginal atrophy. 1, 3
Large trials demonstrate that ospemifene effectively treats vaginal dryness and dyspareunia. 4, 2, 5
Ospemifene is not recommended for women with a history of estrogen‑dependent cancers due to insufficient safety data. 3, 6
Vaginal DHEA improves sexual desire, arousal, pain, and overall sexual function in breast/gynecologic cancer survivors, though safety data in hormonally mediated cancers remain limited. 4, 2

Topical lidocaine can be applied to the vulvar vestibule before intercourse to relieve persistent introital pain and dyspareunia. 4, 1
Pelvic‑floor muscle training may enhance sexual pain, arousal, lubrication, orgasm, and satisfaction, with particular benefit for patients who have pelvic‑floor dysfunction. 4, 2, 5 [1, 3]
Vaginal dilators are useful for women with vaginismus or radiation‑induced vaginal stenosis; they should be introduced early and offered to all women at risk for vaginal changes. 1, 3

Systemic hormone therapy is contraindicated in women with hormone‑sensitive breast cancer. 1
The FDA label for DHEA warns that exogenous estrogens are contraindicated in women with a history of breast cancer. 7
Women with other hormone‑sensitive cancers (endometrial, ovarian) require a thorough discussion of benefits and risks before any hormonal therapy; systemic hormone therapy is not automatically contraindicated in these groups. 1, 3

Do not bypass conservative measures; lubricants and moisturizers should be trialed first unless symptoms are markedly severe. 1, 3
Recognize that vaginal estrogen has a more favorable risk‑benefit profile than systemic estrogen for local symptoms; formulations are not interchangeable. 1, 3, 8
Address concurrent pelvic‑floor dysfunction, as many women with sexual dysfunction have associated pelvic‑floor issues that benefit from physical therapy. 4, 2, 5
Re‑evaluate treatment efficacy and tolerability at regular intervals to ensure optimal symptom control and safety. 4, 5